Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.68 |
| ▸ | TUBB | P07437 | 3/20 | 0.68 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.68 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.68 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.68 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.68 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.68 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.68 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.68 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.68 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.68 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.68 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.68 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.68 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259528 | 1.00 | TUBB4A (0.68) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL23882121 | 0.88 | TUBB4A (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29900514 | 0.87 | KDM4E (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6929589 | 0.87 | KDM4E (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL17298011 | 0.86 | TUBB4A (0.66) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL28012240 | 0.83 | TUBB4A (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3110721 | 0.83 | KDM4E (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL30120616 | 0.83 | KDM4E (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL23882052 | 0.83 | KDM4E (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3117638 | 0.83 | KDM4E (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2023-05-18 | — | — | US | disclosed |
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2023-05-18 | — | — | US | disclosed |
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2023-05-18 | — | — | US | disclosed |
| EP-4126847-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO Pharma (FR) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021198191-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021198188-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021198191-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021198188-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2021-10-07 | — | — | WO | disclosed |
| US-9708332-B2 | Respiratory syncytial virus inhibitors | MEDIVIR AB (SE) | 2017-07-18 | — | — | US | disclosed |
| US-9708332-B2 | Respiratory syncytial virus inhibitors | MEDIVIR AB (SE) | 2017-07-18 | — | — | US | disclosed |
| WO-2015065338-A1 | QUINAZOLINE BASED RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | MEDIVIR AB (SE) | 2015-05-07 | — | — | WO | disclosed |
| WO-2011012622-A1 | BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | NQO2, NQO1, NDUFV2 | TUBB4A 280/4885TUBB 441/4885TUBA3C 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.